Tenaya Therapeutics, Inc. (TNYA) SEC Filings

Tenaya Therapeutics, Inc. (TNYA) reported that Chief Medical Officer Tingley Whittemore received equity awards on September 10, 2026. These include a stock option for 293,000 shares of common stock at an exercise price of $0.6488 per share, vesting monthly over four years, and 49,000 restricted stock units vesting in semiannual installments starting February 15, 2027. Following the RSU grant, Whittemore directly holds 263,073 shares of common stock, including 142,076 shares subject to RSU vesting. No Rule 10b5-1 trading plan is reported.

Tenaya Therapeutics, Inc. (TNYA) is reported to have a significant shareholder group led by Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander under a Schedule 13G. Integrated Core Strategies (US) LLC reports beneficial ownership of 11,579,445 shares of Tenaya common stock. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 11,581,565 shares, representing 5.2% of Tenaya’s outstanding common stock. For each reporting person, sole voting and dispositive power is 0, while shared voting and shared dispositive power correspond to the reported share amounts. The filing also includes a Joint Filing Agreement among the reporting persons.

Tenaya Therapeutics, Inc. director and Chief Executive Officer Ali Faraz reported selling an aggregate 22,232 shares of common stock on 2026-08-17 in four open-market transactions at weighted average prices of about $0.71 per share. Footnotes state each sale covered tax withholding obligations arising from the vesting of restricted stock units granted on February 15, 2023, February 23, 2024, February 6, 2025, and February 3, 2026, respectively. Additional disclosure notes future issuance of 305,956, 295,331, 281,894, and 262,069 shares upon vesting of these restricted stock units.

Tenaya Therapeutics, Inc. Chief Medical Officer Whittemore Tingley reported open-market sales of 7,424 shares of common stock on August 17, 2026 at a weighted average price of $0.7098 per share, with individual trade prices ranging from $0.6820 to $0.7253. Footnotes state these sales were made to cover tax withholding obligations arising from the vesting of restricted stock units granted in 2023, 2024, 2025, and 2026, rather than as discretionary portfolio trades. Related footnotes also note substantial unvested restricted stock units that will be delivered in future, including 108,544, 104,169, 99,169, and 93,076 shares tied to different award dates, plus 6,000 shares acquired under the 2021 Employee Stock Purchase Plan.

Tenaya Therapeutics reported Q2 2026 collaboration revenue of $1,110 (in thousands), its first reported revenue, primarily from a new multi-target research agreement with Alnylam and related collaborations. Total operating expenses rose 88% to $45,198 (in thousands), driven by a $21,821 (in thousands) impairment on its decommissioned Genetic Medicine Manufacturing Center and a $1,368 (in thousands) loss on lease termination, partly offset by lower research and development and general and administrative spending.

The company recorded a Q2 net loss of $43,393 (in thousands) and a six-month net loss of $62,665 (in thousands), compared with $23,283 (in thousands) and $50,147 (in thousands) in 2025. Net cash used in operating activities was $22,786 (in thousands) for the first half, and cash and cash equivalents were $78,085 (in thousands) as of June 30, 2026. Management expects existing cash to fund operations for at least 12 months after filing. Tenaya continues to advance three lead programs: TN-201 and TN-401, AAV9-based gene therapies for genetically defined cardiomyopathies with interim data showing structural, arrhythmia and symptom improvements, and TN-301, an oral HDAC6 inhibitor being positioned for proof-of-activity trials in heart failure with preserved ejection fraction and Duchenne muscular dystrophy.

Tenaya Therapeutics reported second quarter 2026 results and an update on its cardiology pipeline. In the MyPEAK-1 trial, all six evaluable TN-201 patients with MYBPC3-associated hypertrophic cardiomyopathy showed reductions in echocardiographic hypertrophy measures and improvements in symptom burden, and TN-201 was generally well tolerated. The program received EMA PRIority MEdicine designation and entered the FDA Rare Disease Evidence Principles process.

In the RIDGE-1 trial, TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy produced a mean 64% reduction in premature ventricular contraction counts across treated patients, with substantial reductions in non-sustained ventricular tachycardia for two participants and no dose-limiting toxicities. Tenaya expects additional interim data and regulatory updates for TN-201 and TN-401 in the fourth quarter of 2026 and is advancing HDAC6 inhibitor TN-301 toward a Phase 2 start in the second half of 2027.

Financially, collaboration revenue for the quarter was $1,110 (in thousands). R&D and G&A expenses were $16,603 and $5,406 (in thousands), respectively. A $21,821 (in thousands) non-cash impairment charge and $1,368 (in thousands) loss on lease termination contributed to a net loss of $43,393 (in thousands), or $0.20 per share. Cash and equivalents totaled $78.1 million, expected to fund operations through the third quarter of 2027.

Tenaya Therapeutics, Inc. lists Chief Financial Officer Eric J Hyllengren as a reporting person in an initial Form 3 insider ownership report. The structured data show no buy or sell transactions, no derivative positions, and a neutral net buy/sell status at the time of filing.